

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 47/48, G01N 33/74, 33/53, C12P 21/08, G01N 33/531, C12N 5/20, C07D 498/18	A1	(11) International Publication Number: WO 94/25072 (43) International Publication Date: 10 November 1994 (10.11.94)
(21) International Application Number: PCT/US94/04463 (22) International Filing Date: 22 April 1994 (22.04.94) (30) Priority Data: 08/053,030 23 April 1993 (23.04.93) US 08/224,207 14 April 1994 (14.04.94) US (71) Applicant: AMERICAN HOME PRODUCTS CORPORATION [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US). (72) Inventors: MOLNAR-KIMBER, Katherine, Lu; 222 Harrison Avenue, Glenside, PA 19038 (US). OCAIN, Timothy, Donald; 4210 Stearns Hill Road, Waltham, MA 02154 (US). CAUFIELD, Craig, Eugene; 28 Cranbury Road, Princeton, NJ 08550 (US). CAGGLIANO, Thomas, Joseph; 350 Stockham Avenue, Morrisville, PA 19067 (US). FAILLI, Amedeo, Arturo; 14 Landing Lane, Princeton Junction, NJ 08550 (US). (74) Agents: ALICE, Ronald, W.; American Home Products Corporation, Five Giralda Farms, Madison, NJ 07940-0874 (US) et al.		(81) Designated States: AU, BB, BG, BR, BY, CA, CN, CZ, FL, GE, HU, JP, KG, KP, KR, KZ, LK, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: RAPAMYCIN CONJUGATES AND ANTIBODIES (57) Abstract Provided are rapamycin conjugates which are useful as immunogenic molecules for the generation of antibodies specific for rapamycin, for measuring levels of rapamycin or derivatives thereof; for isolating rapamycin binding proteins; and detecting antibodies specific for rapamycin or derivatives thereof.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

RAPAMYCIN CONIUGATES AND ANTIBODIES

BACKGROUND OF THE INVENTION

This invention relates to derivatives of rapamycin which are useful as immunogenic molecules for the generation of antibodies specific for rapamycin or ring
5 opened derivatives thereof, for measuring levels of rapamycin or derivatives thereof; for isolating rapamycin binding proteins; and detecting antibodies specific for rapamycin or derivatives thereof.

Rapamycin is a macrocyclic triene antibiotic produced by Streptomyces hygroscopicus, which was found to have antifungal activity, particularly against
10 Candida albicans, both in vitro and in vivo [C. Vezina et al., J. Antibiot. 28, 721 (1975); S.N. Sehgal et al., J. Antibiot. 28, 727 (1975); H. A. Baker et al., J. Antibiot. 31, 539 (1978); U.S. Patent 3,929,992; and U.S. Patent 3,993,749].

Rapamycin alone (U.S. Patent 4,885,171) or in combination with picibanil (U.S. Patent 4,401,653) has been shown to have antitumor activity. R. Martel et al.
15 [Can. J. Physiol. Pharmacol. 55, 48 (1977)] disclosed that rapamycin is effective in the experimental allergic encephalomyelitis model, a model for multiple sclerosis; in the adjuvant arthritis model, a model for rheumatoid arthritis; and effectively inhibited the formation of IgE-like antibodies.

The immunosuppressive effects of rapamycin have been disclosed in FASEB 3,
20 3411 (1989). Cyclosporin A and FK-506, other macrocyclic molecules, also have been shown to be effective as immunosuppressive agents, therefore useful in preventing transplant rejection [FASEB 3, 3411 (1989); FASEB 3, 5256 (1989); R. Y. Calne et al., Lancet 1183 (1978); and U.S. Patent 5,100,899].

Rapamycin has also been shown to be useful in preventing or treating systemic
25 lupus erythematosus [U.S. Patent 5,078,999], pulmonary inflammation [U.S. Patent 5,080,899], insulin dependent diabetes mellitus [Fifth Int. Conf. Inflamm. Res. Assoc. 121 (Abstract), (1990)], adult T-cell leukemia/lymphoma [European Patent Application 525,960 A1], and smooth muscle cell proliferation and intimal thickening following vascular injury [Morris, R. J. Heart Lung Transplant 11 (pt. 2): 197 (1992)].

- 2 -

Mono- and diacylated derivatives of rapamycin (esterified at the 28 and 43 positions) have been shown to be useful as antifungal agents (U.S. Patent 4,316,885) and used to make water soluble prodrugs of rapamycin (U.S. Patent 4,650,803). Recently, the numbering convention for rapamycin has been changed; therefore
5 according to Chemical Abstracts nomenclature, the esters described above would be at the 31- and 42- positions. U.S. Patent 5,100,883 discloses fluorinated esters of rapamycin. U.S. Patent 5,118,677 discloses amide esters of rapamycin. U.S. Patent 5,118,678 discloses carbamates of rapamycin. U.S. Patent 5,130,307 discloses aminoesters of rapamycin. U.S. Patent 5,177,203 discloses sulfonates and sulfamates
10 of rapamycin. U.S. Patent 5,194,447 discloses sulfonylcarbamates of rapamycin. PCT Publication WO 92/05179 discloses carboxylic acid esters of rapamycin.


Yatscoff has reported that rapamycin levels can be quantitated using HPLC method with a sensitivity of 1 ng/ml [Ther. Drug Monitoring 14: 138 (1992)] This method is time consuming and each sample must be assayed individually.

15 Immunoassays have been developed for numerous proteins as well as various drugs including cyclosporin A [Morris, R.G., Ther. Drug Monitoring 14: 226- (1992)], and FK506 [Tamura, Transplant Proc. 19: 23 (1987); Cadoff, Transplant Proc. 22: 50 (1990)]. Numerous types of immunoassays, that have been developed to measure proteins or compounds, have been based on competitive inhibition, dual
20 antibodies, receptor-antibody interactions, antigen capture, dipstick, antibody or receptor trapping, or on affinity chromatography. Affinity columns with rapamycin have been reported in which a rapamycin analog was covalently attached to a matrix [Fretz J. Am. Chem. Soc. 113: 1409 (1991)]. These columns have been used to isolate rapamycin binding proteins.

25 DESCRIPTION OF THE INVENTION

This invention provides a rapamycin conjugate of formula I, having the structure

- 3 -



wherein R^1 and R^2 are each, independently, hydrogen or $-(R^3-L-R^4)_a$;

L is a linking group;

R^3 is selected from the group consisting of carbonyl, $-S(O)-$, $-S(O)_2$, $-P(O)_2-$, $-P(O)(CH_3)-$, $-C(S)-$, and $-CH_2C(O)-$;

R^4 is selected from the group consisting of carbonyl, $-NH-$, $-S-$, $-CH_2-$, and $-O-$;

$a = 1 - 5$;

$x = 0 - 1$;

$y = 0 - 1$;

z is from about 1 to about 120;

and Carrier is immunogenic carrier material, detector carrier material, or a solid matrix,

or a salt thereof; with the proviso that R^1 and R^2 are not both hydrogen; and

further provided that when a is greater than 1, each L group can be the same or

different; and still further provided that x is 0 if R^1 is hydrogen and y is 0 if R^2

is hydrogen, and if x and y are both 1, the Carrier moiety is the same in both cases.

The linking group, L , is any moiety that contains the group R^3 on one end and R^4 on other end, therefore enabling the linking group to be connected to the 42- and/or 31-hydroxyl groups of rapamycin on one end and connected to another linking group or the immunogenic carrier material, detector material, or matrix on the other end. When a is greater than 1, each R^3 , R^4 or L group can be the same or different. In such

- 4 -


cases, the first L group is designated as L¹, the second L group designated as L² and so on. The rapamycin conjugates of the present invention may be prepared in such ways as to encompass a wide range of linking groups (L) and terminal functional groups R⁴. For example, L may be linear or branched alkylenes comprising from 1 to as many as 15, more usually 10 or less, and normally less than 6 carbon atoms (i.e., methylene, ethylene, n-propylene, iso-propylene, n-butylene, and so forth). In addition, such alkylenes can contain other substituent groups such as cyano, amino (including substituted amino, e.g., mono- or di-alkylamino), acylamino (e.g., alkanoylamino or aroylamino), halogen, thiol, hydroxyl, carbonyl groups, carboxyl (including substituted carboxyls such as esters (e.g., alkyl or aralkyl esters), amides, and substituted amides (e.g., mono- or di-alkylamides). The linking group L can also contain or consist of substituted or unsubstituted aryl (including heteroaryl, e.g., where the heteroatom(s) is (are) selected from one (or more) of oxygen, nitrogen and sulphur) or aralkyl (e.g., phenylene, phenethylene, and so forth). Additionally, such linkages can contain one or more heteroatoms selected from nitrogen, sulfur and oxygen in the form of ether, ester, amido, amino, thio ether, amidino, sulfone, or sulfoxide. Also, such linkages can include unsaturated groupings such as olefinic or acetylenic bonds, disulfide, imino, or oximino groups. Preferably L will be a chain, usually aliphatic comprising between 1 and about 20 atoms, more usually between 1 and 10, excluding hydrogen, of which between 0 and 5 are heteroatoms preferably selected from nitrogen, oxygen, and sulfur. Therefore, the choice of linking group L is not critical to the present invention and may be selected by one of ordinary skill taking normal precautions to assure that stable compounds are produced.

The term "aryl" as a group or part of a group such as arylalkyl includes any carbocyclic aromatic group of 6 to 10 carbon atoms or heteroaromatic group of 5 to 10 ring atoms of which up to 3 are heteroatoms selected from the group consisting of oxygen, nitrogen and sulphur. When the aryl group is substituted, examples of substituents are one or more, the same or different, of the following: alkyl of 1-6 carbon atoms, arylalkyl in which the alkyl portion contains 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, mono- or di-alkylamino of 1-6 carbon atoms per alkyl group, aminocarbonyl, alkylthio of 1-6 carbon atoms, -SO₃H and -CO₂H. The aryl group may be mono- or bi-cyclic.

- 5 -

Examples of alkyl as a group or part of a group, e.g., arylalkyl, alkoxy or alkanoyl (alkylcarbonyl), are straight or branched chains of 1-6 carbon atoms, preferably 1-4 carbon atoms, e.g., methyl, ethyl, propyl, isopropyl and n-butyl.

A preferred embodiment of this invention provides a conjugate of formula II,
5 having the structure



R¹ and R² are each, independently, hydrogen or -R³-L-R⁴-;

L is -A-(CR⁵R⁶)_b[B-(CR⁷R⁸)_d]_e-

A is -CH₂- or -NR⁹-;

10 B is -O-, -NR⁹-, -S-, -S(O)-, or -S(O)₂-;

R³ is selected from the group consisting of carbonyl, -S(O)-, -S(O)₂, -P(O)₂-, -P(O)(CH₃)-, -C(S)-, and -CH₂C(O)-;

R⁴ is selected from the group consisting of carbonyl, -NH-, -S-, -CH₂-, and -O-;

15 R⁵, R⁶, R⁷, and R⁸ are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, halo, hydroxy, trifluoromethyl, arylalkyl in which the alkyl portion contains 1-6 carbon atoms, aminoalkyl of 1-6 carbon atoms, hydroxyalkyl of 1-4 carbon atoms, alkoxy of 1-6 carbon atoms, carbalkoxy of 2-7 carbon atoms, cyano, amino, -CO₂H, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent
20 selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or -CO₂H;

- 6 -

R^9 is hydrogen, alkyl of 1-6 carbon atoms, or aralkyl in which the alkyl portion contains 1-6 carbon atoms, providing that when more than one R^9 group is present they may be the same or different;

$b = 0-10$;

5 $d = 0-10$;

$e = 0-2$;


$x = 0-1$;

$y = 0-1$;

z is from about 1 to about 120;

10 and Carrier is immunogenic carrier material, detector carrier material, or a solid matrix, or a salt thereof with the proviso that R^1 and R^2 are not both hydrogen; and further provided that when b is greater than 1, each of the CR^5R^6 groups can be the same or different, and when d or e is greater than 1, each of the CR^7R^8 groups can be the same or different; and still further provided that x is 0 if R^1 is
 15 hydrogen and y is 0 if R^2 is hydrogen, and if x and y are both 1, the Carrier moiety is the same in both cases.

A second preferred embodiment of this invention provides a conjugate of formula III, having the structure




20 R^1 and R^2 are each, independently, hydrogen or $-(R^3-L^1-R^4)_f-(R^{10}-L^2-R^{11})_g$ -Carrier;

L^1 is $-(CH_2)_h-CHR^{12}-(CH_2)_j-$;

L^2 is $-(CH_2)_k-D-(CH_2)_m-E-$;

- 7 -



R^3 and R^{10} are each, independently, selected from the group consisting of carbonyl, $-\text{S}(\text{O})-$, $-\text{S}(\text{O})_2$, $-\text{P}(\text{O})_2-$, $-\text{P}(\text{O})(\text{CH}_3)-$, $-\text{C}(\text{S})-$, and $-\text{CH}_2\text{C}(\text{O})-$;

5 R^4 and R^{11} are each, independently, selected from the group consisting of carbonyl, $-\text{NH}-$, $-\text{S}-$, $-\text{CH}_2-$, and $-\text{O}-$;

R^{12} is hydrogen, alkyl of 1-6 carbon atoms, arylalkyl in which the alkyl portion contains 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, $-(\text{CH}_2)_n\text{CO}_2\text{R}^{13}$, $-(\text{CH}_2)_p\text{NR}^{14}\text{R}^{15}$, carbamylalkyl of 2-3 carbon atoms, aminoalkyl of 1-4 carbon atoms, hydroxyalkyl of 1-4 carbon atoms, guanylalkyl of 2-4 carbon atoms, mercaptoalkyl of 1-4 carbon atoms, alkylthioalkyl of 2-6 carbon atoms, indolylmethyl, hydroxyphenylmethyl, imidazolylmethyl, halo, trifluoromethyl, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or $-\text{CO}_2\text{H}$;

R^{14} , and R^{15} are each, independently, hydrogen, alkyl of 1-6 carbon atoms, or arylalkyl of 7-10 carbon atoms;

20 R^{13} is hydrogen, alkyl of 1-6 carbon atoms, arylalkyl in which the alkyl portion has 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or $-\text{CO}_2\text{H}$;

25 $f = 0-3$;

$g = 0-1$;

$h = 0-10$;

$j = 0-10$;

$k = 0-10$;

30 $m = 0-10$;

$n = 0-6$;

- 8 -

p = 0-6;


x = 0 - 1;

y = 0-1;

z is from about 1 to about 120;

- 5 and Carrier is immunogenic carrier material, detector carrier material, or a solid matrix, or a salt thereof with the proviso that R^1 and R^2 are not both hydrogen; and further provided that f and g are both not 0 and when f is greater than 1, each of the $-(R^3-L^1-R^4)-$ moieties can be the same or different; and still further provided that x is 0 if R^1 is hydrogen and y is 0 if R^2 is hydrogen, and if x and y are both
- 10 1, the Carrier moiety is the same in both cases.

This invention also provides a conjugate of formula IV, having the structure



wherein R^{16} is $-OCH_2(CH_2)_qR^4-$;

- 15 R^4 is selected from the group consisting of carbonyl, $-NH-$, $-S-$, $-CH_2-$, and $-O-$;
 q = 0 - 6;
 z is from about 1 to about 120;
 and Carrier is immunogenic carrier material, detector carrier material, or a solid matrix, or a salt thereof.

- 20 The immunogenic carrier material can be selected from any of those conventionally known. In most cases, the carrier will be a protein or polypeptide, although other materials such as carbohydrates, polysaccharides, lipopolysaccharides, nucleic acids and the like of sufficient size and immunogenicity can likewise be used.

- 9 -

For the most part, immunogenic proteins and polypeptides will have molecular weights between 5,000 and 10,000,000, preferably greater than 15,000 and more usually greater than 40,000. Generally, proteins taken from one animal species will be immunogenic when introduced into the blood stream of another species. Particularly
5 useful proteins are those such as albumins, globulins, enzymes, hemocyanins, glutelins or proteins having significant non-proteinaceous constituents, e.g., glycoproteins, and the like. Further reference for the state-of-the-art concerning conventional immunogenic carrier materials and techniques for coupling haptens thereto may be had to the following: Parker, Radioimmunoassay of Biologically Active Compounds,
10 Prentice-Hall (Englewood Cliffs, N.J., USA, 1976), Butler, J. Immunol. Meth. 7:1-24 (1975) and Pharmacol. Rev. 29(2):103-163 (1978); Weinryb and Shroff, Drug Metab. Rev. 10:P271-283 (1975); Broughton and Strong, Clin. Chem. 22:726-732 (1976); and Playfair et al., Br. Med. Bull. 30:24-31 (1974). Preferred immunogenic carrier materials for use in the present invention are ovalbumin and keyhole limpet
15 hemocyanin. Particularly preferred for use in the present invention is ovalbumin. The detector carrier material can be a rapamycin-linking moiety conjugated to an enzyme such as horseradish peroxidase, alkaline phosphatase, luciferase, a fluorescent moiety such as fluorescein, Texas Red, or rhodamine, a chemiluminescent moiety, and the like. The solid matrix carrier material can be resin beads, an ELISA plate, glass beads
20 as commonly used in a radioimmunoassay, plastic beads, solid matrix material typically used in a dipstick-type assay. When rapamycin is conjugated to a solid matrix, the resulting conjugate can be used in a dipstick assay, as described in this disclosure, for the affinity purification of antibodies, or for isolating rapamycin binding proteins.

It should be noted that as used in the formulae above describing the specific
25 rapamycin conjugates, z represents the number of rapamycin conjugated to the carrier material. The value z is sometimes referred to as the epitopic density of the immunogen, detector, or solid matrix and in the usual situation will be on the average from about 1 to about 120 and more typically from 1 to 50. The densities, however, may vary greatly depending on the particular carrier material used.

30 When any of the compounds of this invention contain an aryl or arylalkyl moiety, it is preferred that the aryl portion is a phenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, quinoxalyl, thienyl, thionaphthyl, furyl, benzofuryl, benzodioxyl, benzoxazolyl, benzoisoxazolyl, or benzodioxolyl group that may be optionally mono-, di-, or tri- substituted with a group selected from alkyl of 1-6 carbon atoms, arylalkyl
35 of 7-10 carbon atoms, alkoxy of 1-6 carbon atoms, cyano, halo, nitro, carbalkoxy of 2-

- 10 -

7 carbon atoms, trifluoromethyl, amino, dialkylamino of 1-6 carbon atoms per alkyl group, alkylthio of 1-6 carbon atoms, -SO₃H and -CO₂H. It is more preferred that the aryl moiety is a phenyl group that is optionally mono-, di-, or tri- substituted with a group selected from alkyl of 1-6 carbon atoms, arylalkyl of 7-10 carbon atoms, alkoxy of 1-6 carbon atoms, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, dialkylamino of 1-6 carbon atoms per alkyl group, alkylthio of 1-6 carbon atoms, -SO₃H and -CO₂H.

The salts are those derived from such inorganic cations such as sodium, potassium, and the like; organic bases such as: mono-, di-, and trialkyl amines of 1-6 carbon atoms, per alkyl group and mono-, di-, and trihydroxyalkyl amines of 1-6 carbon atoms per alkyl group, and the like; and organic and inorganic acids as: acetic, lactic, citric, tartaric, succinic, maleic, malonic, gluconic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly known acceptable acids.

This invention also provides a process for preparing the rapamycin conjugates and antibodies of this invention. In particular this invention provides a process for preparing rapamycin conjugates including those of formula I and IV as defined above which comprises:

reacting a compound of formula (V) or (VI):

31-(OR²¹), 42-(OR²²) rapamycin (V)

or

27-(=N-R²³) rapamycin (VI)

wherein R²¹ and R²² are each selected from hydrogen or -(R³-L-R⁴)_a-T¹ providing that R²¹ and R²² are not both hydrogen (i.e. when both R²¹ and R²² are hydrogen the compound of formula (V) is rapamycin);

R²³ is -O(CH₂)(CH₂)_qR⁴-T¹;

-(R³-L-R⁴)_a- is a group as defined above;

T¹ is an electrophilic or nucleophilic group depending on the value for R⁴; and

q and R⁴ are as hereinbefore defined;

with a carrier material or matrix having available at least z nucleophilic or electrophilic groups; said carrier being represented by the formula

[T²]_z-Carrier

(where Carrier and z are as defined above and T² is a nucleophilic or electrophilic group of the carrier);

- 11 -

providing that in the formulae above when one of T¹ and T² is a nucleophilic group the other is an electrophilic group such that the bonding to the carrier is via a group R⁴ as defined above.

Accordingly, the compounds of this invention can be prepared by reacting the
5 42- and/or 31-hydroxyl groups of rapamycin with a suitable electrophilic reagent that will serve as the linker moiety. The following patents exemplify the preparation of the 42- and/or 31-derivatives of rapamycin that can be used as linking groups for the preparation of the compounds of this invention. The preparation of fluorinated esters of rapamycin is described in U.S. Patent 5,100,883. The preparation of amide esters is
10 disclosed in 5,118,677. The preparation of carbamates of rapamycin is disclosed in U.S. Patent 5,118,678. The preparation of aminoesters of rapamycin is described in U.S. Patent 5,130,307. The preparation of sulfonates and sulfamates of rapamycin are described in U.S. Patent 5,177,203. The preparation of sulfonylcarbamates of rapamycin are described in U.S. Patent 5,194,447. The disclosures of the above cited
15 U.S. Patents are hereby incorporated by reference. From these patents, it can be seen that reactive electrophiles such as isocyanates, used in the preparation of carbamates, or sulfonyl chlorides, used in the preparation of sulfonates, can be reacted with the hydroxyl groups of rapamycin without the need for an activating agent. For the esterification of the rapamycin hydroxyl groups with a carboxylic acid, activation is
20 usually required through the use of a coupling reagent such as DCC, or a water soluble analog thereof, such as dimethylaminopropyl)-3-ethyl carbodiimide (DAEC). Representative examples of the preparation of rapamycin-linking group moieties are provided as examples below. The preparation of ether derivatives of rapamycin can be accomplished using the methodology disclosed in Example 18.

25 For the compounds of this invention in which the linker group is attached to the 42- or the 31,42-hydroxyls, the electrophile (or activated electrophile) is reacted with rapamycin to typically provide a mixture of the 42- and 31,42-derivatized rapamycin that can be separated by chromatography. For the compounds of this invention in which the linker group is attached to the 31-hydroxyl of rapamycin, the 42-hydroxyl
30 group must be protected with a suitable protecting group, such as with a tert-butyl dimethyl silyl group. The 31-hydroxyl can then be reacted with a suitable electrophile to provide the derivatized rapamycin, followed by deprotection of the 42-hydroxyl group. The preparation of 42-O-silyl ethers of rapamycin and subsequent deprotection is described in U.S. Patent 5,120,842, which is hereby incorporated by
35 reference. Preparation of compounds containing different linkers at the 31- and 42-

- 12 -

positions can be accomplished by first preparing the 42-derivatized compound and then using a different linker to derivatize the 31-position. The preparation of the 27-oxime linking groups can be accomplished using the methodology disclosed in U.S. Patent 5,023,264, which is hereby incorporated by reference; and as described in Example 21.

5 The linker group attached to rapamycin can be coupled to a second linker group using standard methodology described in the peptide literature; typically by activating the electrophilic moiety, with DCC type coupling reagent, or with N-hydroxysuccinimide, or as an activated ester or anhydride. The activated electrophilic end of one linking moiety can then be reacted with the nucleophilic end of the other
10 linker moiety.

 The coupling of the rapamycin linking group moiety to the immunogenic carrier can be accomplished under standard literature conditions. In general, for reaction with a nucleophilic group on the immunogenic carrier material, an electrophilic moiety, such as a carboxylic acid, on the linking group is activated with a suitable activating agent
15 such as N-hydroxysuccinimide, and then reacted with the nucleophilic moiety on the immunogenic carrier material. Examples 2 and 3 specifically exemplify this technique. Similar methodology is employed for the coupling of a nucleophilic moiety on the linking group to an electrophilic moiety on the immunogenic carrier material. In such cases, the electrophilic moiety on the immunogenic carrier material is activated as
20 described above, and then reacted with the nucleophilic end of the linking group. If desired the linking group can be attached to the carrier and then reacted with rapamycin at the 42- and/or 31-hydroxy function.

 The reagents used to prepare the compounds of the invention are commercially available or can be prepared by methods that are disclosed in the literature.

25

 This invention also covers analogous conjugates of other rapamycins such as, but not limited to, 29-demethoxyrapamycin, [U.S. Patent 4,375,464, 32-demethoxyrapamycin under C.A. nomenclature]; rapamycin derivatives in which the double bonds in the 1-, 3-, and/or 5-positions have been reduced [U.S. Patent
30 5,023,262]; 42-oxorapamycin [U.S. Patent 5,023,262]; 27-oximes of rapamycin [U.S. Patent 5,023,264]; 27-hydrazones of rapamycin [U.S. Patent 5,120,726]; 29-desmethylrapamycin [U.S. Patent 5,093,339, 32-desmethylrapamycin under C.A. nomenclature]; 7,29-bisdesmethylrapamycin [U.S. Patent 5,093,338, 7,32-desmethylrapamycin under C.A. nomenclature]; and 15-hydroxy- and 15,27-bishydroxy- rapamycin [U.S. Patent 5,102,876]. The disclosures in the above cited
35 U.S. Patents are hereby incorporated by reference. Also covered are conjugates of the

- 13 -

rapamycin 1,3-Diels Alder adduct with diethyl azidodicarboxylate and rapamycin 1,3-Diels Alder adduct with phenyltriazoline dione. The preparation of these compounds is described in Examples 14 and 15.

5 The compounds of this invention are rapamycin immunogen, detector, and matrix bound conjugates that are useful for the generation and detection of antibodies specific for rapamycin and derivatives thereof, for measuring levels of rapamycin or a derivative thereof in biological or laboratory fluids, and for isolating rapamycin binding proteins. Rapamycin derivatives as defined here are compounds containing a
10 rapamycin nucleus, a metabolite of rapamycin, or a ring opened rapamycin (such as secorapamycin, described in U. S. Patent 5,252,579, which is hereby incorporated by reference), in which one or more of the hydroxyl groups has been esterified into a carboxylic ester, a carbamate, a sulfonate ester, an amide, or the like, or one or more of the ketones has been reduced to a hydroxyl group, or one or more of the double bonds
15 has been reduced, or one ketones has been converted to an oxime or a hydrazone. Other rapamycin derivatives for which the compounds of this invention can be used for measuring levels of or generating antibodies to will be apparent to one skilled in the art based on this disclosure.

Antibodies specific for rapamycin or a derivative thereof using the rapamycin
20 immunogen conjugates of this invention may be generated by standard techniques that are known in the art. Typically, a host animal is inoculated at one or more sites with the immunogen conjugate, either alone or in combination with an adjuvant. The typical host mammals include, but are not limited to, mice, goats, rabbits, guinea pigs, sheep, or horses. Subsequent injections can be made until a sufficient titer of antibodies are
25 produced. The antibodies generated from the rapamycin immunogen conjugates of this invention can be used in numerous immunoassays, for determining rapamycin levels, in ELISAs, radioimmunoassays, in chemiluminescence immunoassays, and in fluorescent immunoassays. Although many variations of the immunoassay can be used (antigen capture, antibody capture, competitive inhibition, or two antibody
30 immunoassay), a basic competitive inhibition immunoassay can be performed as follows: Antibody specific for the ligand is usually bound to a matrix. A solution is applied to decrease nonspecific binding of the ligand to the matrix. After rinsing the excess away, the antibody coupled matrix may be treated in some cases so it can be stored. In a competitive inhibition assay, the ligand standard curve is made and added
35 with the rapamycin detector conjugate to compete for binding to the rapamycin-specific antibody. If necessary, the excess is removed. The detector molecule is detected by

- 14 -

the standard methods used by one skilled in the art. Different formats can be used, which include but are not limited to, dipstick assays, FPIA, EMIT, ELISA, VISTA, RIA, and MEIA. Detector conjugates of the present invention can be prepared to use in the above assays. For example, the detector conjugates can be Carrier material with
5 labeled fluorescent, chemiluminescent, or enzymatic moieties.

This invention also provides for the use of the rapamycin immunogen conjugates or antibodies specific for rapamycin or a derivative thereof in a test kit that can be commercially marketed. The test kit may be used for measuring levels of rapamycin in biological or laboratory fluids. Test kit components may include
10 antibodies to rapamycin or a derivative thereof, antisera, or rapamycin carrier conjugates. The conjugates or antibodies may be bound to a solid matrix, and rapamycin derivatives or antibodies may be radiolabeled if the assay so requires. Standard concentrations of rapamycin can be included so that a standard concentration curve can be generated. Suitable containers, microtiter plates, solid supports, test
15 tubes, trays, can also be included in any such kit. Many variations of reagents can be included in the kit depending on the type of assay used.

The following is illustrative of the use of a rapamycin immunogen conjugate of this invention to generate antibodies specific for rapamycin or a derivative thereof and detect
20 them using an ELISA format immunoassay. Five mice were immunized with 50 µg rapamycin 31,42-diester with glutaric acid conjugate with keyhole limpet hemocyanin in Complete Freund's Adjuvant) intrasplenically and after about one month were boosted with 50 µg of rapamycin 31,42-diester with glutaric acid conjugate with
keyhole limpet hemocyanin in incomplete Freund's Adjuvant) into the footpads.
25 Microtiter plates (Immunolon D) were coated overnight with 100 µl of goat anti-mouse antibody (10 µg/ml in 10 mM potassium phosphate buffer, pH 7.2) at 4° C. The plates were flicked and blocked with 100 µl of 1% bovine sera albumin in phosphate buffered saline overnight at 4° C. After flicking and washing the plates thrice with 10 mM
phosphate buffer, pH 7.05, 30 mM NaCl, 0.02% Triton X-100, and 0.004%
30 thimerosal wash buffer, 100 µl of each mouse sera diluted with phosphate buffer solution was added to a well and incubated at room temperature for overnight. After flicking and washing the plates thrice with wash buffer, rapamycin 31,42-diester with glutaric acid conjugate with horseradish peroxidase (compound of Example 10 (100 µl, 0.5 ng/ml) was added and incubated for 1 hour at room temperature in the dark. After
35 flicking and washing the plates thrice with wash buffer, tetramethyl benzidine (TMB) substrate with H₂O₂ was added and the plates were incubated covered for 30 min. at

- 15 -

room temperature in the dark. The optical density was read on a spectrophotometer at 450 nm. As shown in Table I, five of the five mice had antibodies reactive for rapamycin 31,42-diester with glutaric acid conjugate with horseradish peroxidase (compound of Example 10).

5

TABLE I

MOUSE #	DILUTION ^a	O.D.
6902	1/300	0.199
6903	1/100	0.231
6904	1/500	0.412
6905	1/100	0.121
6906	1/300	0.321
background	--	0.076

^a Dilution of mouse sera in PBS

10

The results in Table 1 show that mouse 6904 produced the most antibodies to the compound of Example 10. Hybridomas were generated using standard methodology. Following a splenectomy of a mouse immunized and boosted 3 times with the compound of Example 4, spleen cells were fused to SP20 cells to produce hybridomas. The hybridomas were evaluated for the production of antibodies specific for rapamycin or a derivative thereof using an ELISA assay as briefly described below.

15

20

25

Microtiter plates (Immunolon I) were coated overnight with 100 µl of goat anti-mouse antibody (10 µg/ml in 10mM potassium phosphate buffer, pH 7.2) at 4° C. The plates were flicked and blocked with 100 µl of 1% bovine sera albumin in phosphate buffered saline (PBS) overnight at 4° C. After flicking and washing the plates thrice with 0.2x PBS containing 0.02% Triton X-100 and 0.004% thimerosal, 100 µl of each hybridoma supernatant was added to a well and incubated at room temperature for overnight. After flicking and washing the plates thrice with 0.2x PBS containing 0.02% Triton X-100 and 0.004% thimerosal, the compound of Example 22 (100 µl, 0.17 µM) was added and incubated for 1 hour at 4° C. After flicking and washing the plates thrice with 0.2x PBS containing 0.02% Triton X-100 and 0.004% thimerosal, strepavidin or avidin conjugated to horseradish peroxidase (100 µl, 0.2 µg/ml) was added and incubated at room temperature for 1 hour in the dark. After flicking and

- 16 -

washing the plates thrice with 0.2x PBS containing 0.02% Triton X-100 and 0.004% thimerosal, TMB substrate and H₂O₂ was added and the plates were incubated covered for 30 min. at room temperature in the dark. The optical density was read on a spectrophotometer at 450 nm. An optical density reading of 0.25 - 3 indicates specific antibody binding. The results in Table 2 show that the hybridoma from well P4G1 is positive for binding to the compound of Example 22, and is therefore specific for rapamycin or a derivative thereof.

TABLE 2
Screening for Monoclonal Antibodies Specific for
Rapamycin or a Derivative Thereof

WELL	OPTICAL DENSITY
P3H4	0.120
P3H5	0.105
P4G1	1.940

The hybridoma cell line in P4G1 was cloned by limiting dilution and is designated as hybridoma cell line, RAP-42-OVAF₂#1hc-. The hybridoma cell line, RAP-42-OVAF₂#1hc, was deposited under the terms of the Budapest Treaty with the American Type Culture Collection (ATCC) of 12301 Parklawn Drive, Rockville, Maryland, 20852, USA, on March 10, 1994, and was granted accession number HB 11568. In a Fluorescent Polarization Immunoassay (FPIA), rapamycin 42-ester with succinic acid conjugate with 5-glycinyfluoresceinamine was used as a tracer at a concentration of 10nM and showed a polarization of 77mP in 100mM sodium phosphate pH 7.5. After addition of an excess of FKBP12, the polarization measured 195mP whereas the addition of excess of RAP-42-OVAF₂#1MoAb yielded 84mP. The ring opened non-enzymatically transformed product of the above tracer (secorapamycin 42-ester with succinic acid conjugate with 5-glycinyfluoresceinamine) was isolated on TLC plate (50:chloroform:4 methanol:0.5 acetic acid; migrated slowest of three components). The slowest migrating material, termed A3, had a background reading of 75 mP and a reading of 178 mP in presence of RAP-42-OVAF₂#1MoAb. Background levels were observed in the presence of FKBP12 (79 mP). Competition of the binding between the antibody and A3 tracer with rapamycin or securapamycin at 3 min was 155 mP and 105 mP, respectively and after 38 min. gives 121 mP and 89

- 17 -

mP, respectively. The ring opened rapamycin-specific antibody, designated as RAP-42-OVAF₂#1MoAb, was isolated and purified using conventional methodology.

5 The compounds of Examples 12 and 13 can be used in an assay for the detection of polyclonal antibodies and monoclonal antibodies specific for rapamycin or a derivative thereof as described below.

Microtiter plates (Immunolon I) were coated overnight with 100 μ l of goat anti-mouse antibody (10 μ g/ml in 10mM potassium phosphate buffer, pH 7.2) at 4° C. The plates were flicked and blocked with 100 μ l of 1% bovine sera albumin in phosphate buffered saline overnight at 4° C. After flicking and washing the plates thrice with wash buffer, 100 μ l of rabbit sera diluted 1:5 in phosphate buffered saline was added to a well and incubated at room temperature for overnight. After flicking and washing the plates thrice with wash buffer, rapamycin 42-ester with 3-[3-(4-imino-butylthio)succinimidyl]phenacylglycine conjugate with horseradish peroxidase (compound of Example 12) (100 μ l, 0.5 ng/ml) or rapamycin 42 ester with (N-(3-carboxyphenyl)-3-thiosuccinimidyl)glycine conjugate with horseradish peroxidase (compound of Example 13) (100 μ l, 0.5 ng/ml) was added and incubated for 1 hour at room temperature in the dark. After flicking and washing the plates thrice with wash buffer, TMB substrate with H₂O₂ was added and the plates were incubated covered for 20 30 min. at room temperature in the dark. The optical density was read on a spectrophotometer at 450 nm. The results are shown in Table III.

TABLE 3

25 **Comparison of Anti-rapamycin Antibody Levels in Rabbits Immunized with the Compound of Example 3 vs. Naive Rabbits Using a Capture ELISA Assay**

30 Rabbit No.	Prebleed Example 10	Δ A450 (3rd Bleed-Prebleed)		
		Example 10	Example 12	Example 13
81	0.119	0.713	0.217	0.114
89	0.136	0.037	0.026	0.020

35 The data in Table 3 show that the compounds of Examples 12 and 13 can be used to detect antibodies specific for rapamycin or a derivative thereof in a mammal, as seen in rabbit number 81.

- 18 -

The following is an example of the measurement of rapamycin concentrations using a competitive inhibition assay for rapamycin with an ELISA format using an antibody specific for rapamycin. Microtiter plates (Immunolon I) were coated overnight with 100 μ l of goat anti-mouse antibody (10 μ g/ml in 10 mM potassium phosphate buffer, pH 7.2) at 4° C. The plates were flicked and blocked with 100 μ l of 1% bovine sera albumin in phosphate buffered saline overnight at 4° C. After flicking and washing the plates thrice with wash buffer, the rapamycin specific antibody described above (100 μ l of 1 μ g/ml) was added to each well and incubated at room temperature for 1-4 hour. After flicking and washing the plates thrice with wash buffer, rapamycin 31,42-bis(hemiglutarate) conjugate with horseradish peroxidase (100 μ l, 0.5 ng/ml) was added and incubated for 1 hour at room temperature in the dark. After flicking and washing the plates thrice with wash buffer, TMB substrate was added and the plates were incubated covered for 5 min at room temperature in the dark. The optical density was read on a spectrophotometer at 450 nm. Results of the competition between rapamycin and rapamycin 31,42-diester with glutaric acid conjugate with horseradish peroxidase binding to mouse sera are shown in Table 4. From these results, a standard curve can be constructed and the concentration of rapamycin in a sample can be determined.

20

TABLE 4

Free RAPAMYCIN	OPTICAL DENSITY x1000			% Inhibition
	<u>1</u>	<u>2</u>	<u>Avg</u>	
10 μ M	158	158	158	74.1
5	182	194	188	69.2
0.5	304	322	313	48.6
0.05	494	501	498	18.4
0.005	528	546	537	11.9
0.0005	601	611	606	0.6
0	583	636	610	--

25

The compound of Example 11 (rapamycin 42-ester with N-[9H-fluoren-9-ylmethoxy]carbonyl]glycine) can be deprotected by the procedure used in Example 12 (to give rapamycin 42-ester with glycine) and conjugated to a solid matrix. It can bind antibodies specific for rapamycin or a derivative thereof as used in some dipstick

- 19 -

immunoassay methods or to isolate rapamycin binding proteins. The following example illustrates that 803 resonance units (RU) of the compound of Example 11 can be immobilized on a solid matrix using the BIAcore's standard protocol based on EDC and NHS used in a BIAcore. This matrix bound 1401 RU units of rapamycin specific antibody. The kinetics of association and dissociation were determined for each concentration of antibody tested (0.625, 1.25, 2.5, 5.0, 10.0 ug/ml). These data show that the compound of Example 11, even when bound to a matrix was accessible to binding by a ring opened rapamycin-specific antibody and the interaction could be characterized. Similar procedures can be used to bind a rapamycin-binding protein to deprotected rapamycin 42-ester with N-[9H-fluoren-9-ylmethoxy)carbonyl]glycine conjugated matrix. This matrix can also be used for the isolation of novel binding proteins, as practiced by one skilled in the art. Deprotected rapamycin 42-ester with N-[9H-fluoren-9-ylmethoxy)carbonyl]glycine can be used to isolate binding proteins of rapamycin-FKBP complex by one of the following methods. In one approach, tissue or cell lysates containing the appropriate protease inhibitors are incubated with FKBP which has been incubated with a deprotected-rapamycin 42-ester with N-[9H-fluoren-9-ylmethoxy)carbonyl]glycine conjugated matrix for a sufficient time to allow binding. Various buffers are used to rinse the proteins which are nonspecifically bound. Proteins are released by the addition of additional buffers which disrupt the bond between the rapamycin nucleus-FKBP and the binding proteins.

The following examples represent the preparation of representative compounds of this invention.

25

Example 1

Rapamycin 42-ester with succinic acid

1.1 g (11mmol) of succinic anhydride and 400 mg of dimethylaminopyridine (DMAP) were added to a stirring solution of 5g (5.5mmol) of rapamycin and 880 µl of pyridine in 15 ml of methylene chloride. The reaction mixture was stirred for 2 days at room temperature, diluted with methylene chloride and washed with three 50 ml portions of 1N HCl. The organic layer was then dried over Na₂SO₄ and concentrated in vacuo affording crude product. Pure material was obtained by reverse phase HPLC with 55% acetonitrile/water as eluant affording 1g (18%) of the title compound. Spectral data follows: ¹H NMR (CDCl₃, 300 MHz) 4.650 (m, 1H, H₂COC=O), 4.168 (d, 1H, H₂COH), 2.795 (s, 4H, OC=OCH₂CH₂C=O).

- 20 -

Exempl 2**Rapamycin 42-ester with (N-hydroxysuccinimide(hemisuccinate))**

21 mg (0.098 mmol) of DCC and 12 mg (0.098 mmol) of N-hydroxysuccinimide were added to a stirring solution of 100 mg of rapamycin 42-ester with succinic acid in 3 ml ethyl acetate. The reaction mixture was stirred overnight at room temperature, filtered, and concentrated in vacuo affording crude product. Pure material was obtained by reverse phase HPLC with 80% acetonitrile/water as eluant affording 75 mg (69%) of the title compound. Spectral data follows: ¹H NMR (CDCl₃, 300 MHz) 4.650 (m, 1H, H₂COC=O), 4.168 (d, 1H, H₂COH), 2.951 (m, 2H, OC=OCH₂), 2.795 (m, 4H, OC=OCH₂CH₂C=O), 2.705 (m, 2H, OC=OCH₂); MS (neg.ion FAB) 1110 (M⁻), 1056, 1012, 913, 148 (100).

Example 3**Rapamycin 42-ester with succinic acid conjugate with keyhole limpet hemocyanin**

197 mg of keyhole limpet hemocyanin in 6 ml of 0.05 M phosphate buffer was added to a stirring solution of 37 mg of rapamycin 42-ester with (N-hydroxysuccinimide(hemisuccinate)) in 3 ml of 1,4 dioxane and the reaction was left stirring for 3 days at 4°C. The reaction mixture was then dialyzed for 24 hr at 4°C in 1500 ml of 0.05 M phosphate buffer to give the title compound which could be used without further purification. The number of rapamycin 42-ester with succinic acid moieties per keyhole limpet hemocyanin was approximately 42:1.

Example 4**Rapamycin 42-ester with succinic acid conjugate with ovalbumin**

197 mg of ovalbumin in 6 ml of 0.05 M phosphate buffer was added to a stirring solution of 37 mg of rapamycin 42-ester with (N-hydroxysuccinimide(hemisuccinate)) in 3 ml of 1,4 dioxane and the reaction was left stirring for 3 days at 4°C. The reaction mixture was then dialyzed for 24 hr at 4°C in 1500 ml of 0.05 M phosphate buffer to give the title compound which could be used without further purification.

- 21 -

Example 5**Rapamycin 42-ester with succinic acid conjugate with horseradish peroxidase**

16 mg of horseradish peroxidase in a solution of 0.4 ml of 1,4 dioxane and 0.4 ml of 0.5% sodium bicarbonate was added to 1 mg of rapamycin 42-ester with (N-hydroxysuccinimide(hemisuccinate)) in 40 µl of 1,4 dioxane and the reaction left stir for 2.5 hr at 4°C. The reaction mixture was then dialyzed for 24 hr at 4°C in 1500 ml of 0.05 M phosphate buffer to give the title compound which could be used without further purification.

10

Example 6**Rapamycin 31,42 diester with glutaric acid**

The title compound was prepared according to the method used in Example 1.

15

Example 7**Rapamycin 31,42-diester with (N-hydroxysuccinimide(hemiglutarate))**

To a solution of 15.9 mg of rapamycin 31,42-diester with glutaric acid in 160 µL of dimethyl formamide was added 3.65 mg of N,N-dimethylaminopropyl-ethylcarbodiimide and 1.8 mg of N-hydroxysuccinimide. The reaction mixture was allowed to stir until reaction was complete, poured into water, and extracted with ethyl acetate. The organic layers were combined, dried over sodium sulfate, filtered, and concentrated in vacuo to give the title compound, which was stored at 4°C at 0.1 N sodium phosphate buffer and used without further purification.

20

Example 8**Rapamycin 31,42-diester with glutaric acid conjugate with keyhole limpet hemocyanin**

To 20 mg of keyhole limpet hemocyanin in 2 mL of 0.1 M NaHCO₃ was added 55 µL of rapamycin 31,42-diester with (N-hydroxysuccinimide(hemiglutarate)) at 0°C in 10 µL increments over a 30 min period. The solution was gently shaken until reaction was complete, centrifuged at 6000 rpm for 20 min, and unconjugated starting material was separated from the title compound on a G-25 column with phosphate buffer solution. The conjugate was mixed with glycerol at 50% and stored at -70°C. The number of rapamycin 31,42-diester with glutaric acid moieties per keyhole limpet hemocyanin ranged from 17-45:1.

25
30
35

- 22 -

Example 9**Rapamycin 31,42-diester with glutaric acid conjugate with ovalbumin**

To 20 mg of ovalbumin in 2 mL of 0.1 M NaHCO₃ was added 55 µL of rapamycin 31,42-diester with (N-hydroxysuccinimide(hemiglutarate)) at 0°C in 10 µL increments over a 30 min period. The solution was gently shaken until reaction was complete, centrifuged at 6000 rpm for 20 min, and unconjugated starting material was separated from the title compound on a G-25 column with phosphate buffer solution. The conjugate was mixed with glycerol at 50% and stored at -70°C.

10

Example 10**Rapamycin 31,42-diester with glutaric acid conjugate with horseradish peroxidase**

To 10 mg of horseradish peroxidase in 1 mL of 0.1 M NaHCO₃ was added 105 µL of rapamycin 31,42-diester with (N-hydroxysuccinimide(hemiglutarate)) in 10 µL increments over a 30 min period. The solution was gently shaken until complete, centrifuged at 6000 rpm for 20 min, and eluted from a G-25 column with phosphate buffer solution. The conjugate was mixed with glycerol at 50% and stored at -20°C.

Example 11**Rapamycin 42-ester with N-[9H-fluoren-9-ylmethoxy]carbonyl]glycine**

To a chilled (0°C) solution of rapamycin (0.73 g, 0.08 mmol) in methylene chloride (5 mL) was added 0.6 g (1.19 mmol) of N-[9H-fluoren-9-ylmethoxy]carbonyl]glycine pentafluorophenyl ester, followed by pyridine (0.85 mL, 10.5 mmol) and dimethylaminopyridine (18 mg, 0.14 mmol) to form a heterogeneous solution, which became homogeneous upon warming to room temperature. The reaction mixture was stirred at room temperature overnight. A large excess of EtOAc was added. The organic layer was washed with 0.5 N HCl (2x) and brine, dried (MgSO₄), and concentrated to yield an off-white foam. Flash chromatography (30-50% hexane/EtOAc) yielded the title compound in 71% yield (0.679 g, 0.57 mmol). Mass spec (negative ion FAB) M⁻ at m/z 1192.

Example 12**Rapamycin 42-ester with 3-[3-(4-iminobutylthio)succinimidyl]phenacyl-glycine conjugate with horseradish peroxidase**

To a solution of rapamycin 42-ester with N-[9H-fluoren-9-ylmethoxy]-carbonyl]glycine (10 mg, 8.4 µmol) in acetonitrile (84 µL) was added 10 µL (in

- 23 -

acetonitrile at 0.84 M) of diethylamine. The reaction mixture was stirred at room temperature for 60 minutes and the solvent was removed with a stream of nitrogen. The residue was dissolved in acetonitrile (100 μ L) and washed with hexane (5 times, 200 μ L), followed by concentration of the solvent with a nitrogen stream. The resulting rapamycin 42-ester with glycine was taken up in a solution of m-maleimidobenzoyl-N-hydroxysuccinimide (MBS) (2 mg) in DMF (200 μ L) and allowed to incubate for two hours at 4°C, followed by the addition of 50 nM ethanolamine (20 μ L) in 50 mM Tris HCl, pH 8.0. Horseradish peroxidase (5 mg) and Rabbit IgG (10 mg) were treated with 2-iminothiolane and purified with Sephadex G-25, followed by the addition of the MBS-rapamycin glycine ester adduct. The mixture was incubated overnight at 4°C and purified by gel filtration on Sephadex G-25 to provide the title compound.

Example 13

Rapamycin 42 ester with (N-(3-carboxyphenyl)-3-thiosuccinimidyl)-glycine conjugate with horseradish peroxidase

To a solution of rapamycin 42-ester with N-[9H-fluoren-9-ylmethoxy)-carbonyl]glycine (10 mg, 8.4 μ mol) in acetonitrile (84 μ L) was added 10 μ L (in acetonitrile at 0.84 M) of diethylamine. The reaction mixture was stirred at room temperature for 60 minutes and the solvent was removed with a stream of nitrogen. The residue was dissolved in acetonitrile (100 μ L) and washed with hexane (5 times, 200 μ L), followed by concentration of the solvent with a nitrogen stream. The resulting rapamycin 42-ester with glycine was taken up in a solution of N-succinimidyl S-acetylthioacetate (2 mg) in DMF (200 μ L). The reaction mixture was stirred at room temperature for 15 minutes and then at 4°C overnight. A solution of hydroxylamine HCl (7 mg in 50 μ L DMF) was added to the solution of rapamycin reaction mixture, incubated for one hour, followed by the addition of MBS-horseradish peroxidase adduct and MBS-Rabbit IgG to give the title compound which was purified by Sephadex G-25 gel filtration.

Example 14

Rapamycin 1.3. Diels Alder adduct with diethyl azodicarboxylate

Rapamycin (1g, 1.093 mmol) and diethyl azodicarboxylate (0.381 g, 2.187 mmol) were dissolved in dichloromethane (10 ml) and heated at 65°C overnight, TLC showed that the reaction was complete. The mixture was purified on a silica gel

- 24 -

column using ethyl acetate as eluant to provide a white solid (0.750 g) which was triturated with hexane and air dried to give the title compound (0.666 g) as a powder.

Anal Calc for $C_{57}H_{89}N_3O_{17}$: C, 62.91; H, 8.24; N, 3.86. Found: C, 62.81; H, 8.12; N, 3.91

5 IR (KBr, cm^{-1}) 3450, 1720

NMR ($CDCl_3$) δ 6.15 (m, 1H), 5.20 (d, 1H), 3.40 (s, 3H), 3.30 (s, 3H), 3.15 (s, 3H), 0.9 (t, 3H), 0.72 (q, 1H)

MS (-FAB) 1087 (M^-)

10

Example 15

Rapamycin 1.3, Diels Alder adduct with Phenyltriazolinedione

Rapamycin (0.66g, 721 μ mol) was dissolved in dichloromethane (10 ml) and cooled to 0°C. To this was added, dropwise, a solution of phenyltriazolinedione (0.133 g, 758 μ mol) in dichloromethane (10 ml). The solution was stirred overnight, TLC showed the reaction was not complete. Additional phenyltriazolinedione (0.025g, 27 μ mol) was added. The reaction was purified using HPLC (4.1x31cm, SiO_2) with ethyl acetate as eluant to provide the title compound as a solid. The solid was triturated with 30 ml of hexane and 1 ml of ethyl acetate filtered and air dried to give the title compound as a powder (0.383 g).

15

20 Anal Calc for $C_{59}H_{84}N_4O_{15}$: C, 65.05; H, 7.77; N, 5.14. Found: C, 65.39; H, 7.98; N, 4.92

IR (KBr, cm^{-1}) 3450, 1715

NMR (DMSO) δ 7.50 (m, 3H), 7.40 (m, 2H), 3.11 (s, 3H), 3.00 (s, 3H), 2.95 (s, 3H), 0.8 (q, 1H)

25

MS (-FAB) 1088 (M^-)

The following are representative examples of fluorescent rapamycin derivatives that can be conjugated via a linker at the 31-position of rapamycin.

30

Example 16

42-Dansylrapamycin

Rapamycin (200 mg, 0.22 μ mol) in dry pyridine (2 ml) was cooled to 0°C and was treated with dansyl chloride (840 mg, 3.1 μ mol). The reaction was warmed to room temperature and stirred for 24 hours. The reaction mixture was poured into cold 2N HCl (30 ml) and was extracted with ethyl acetate (4x25 ml). The ethyl acetate was pooled and washed with brine, dried over $MgSO_4$, filtered and concentrated in vacuo.

35

- 25 -

The residue was chromatographed on silica with 25% ethyl acetate in benzene. This afforded 150 mg of the title compound as a yellow powder, mp 101-104°C.

Example 17

5 Rapamycin 42-ester with pyrene butyric acid

Rapamycin (459 mg, 0.5 mmol) and pyrenebutyric acid (216 mg, 0.75 mmol) were dissolved in THF/CH₂Cl₂ (10 ml, 1:1). 1-(3-Dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (146 mg, 0.67 mmol) and 4-dimethylaminopyridine (15 mg) were added to the solution. The reaction was allowed to warm to room temperature over 15 hours. The reaction was diluted with CH₂Cl₂ and washed with 5% HCl, then brine. The solution was dried over MgSO₄, filtered and evaporated to a solid. The solid was applied to a 3 mm silica gel Chromatron plate which was eluted with 50% ethyl acetate in hexane to provide 180 mg of the title compound as a foam. The reaction also afforded 100 mg of 31,42-diesterified rapamycin.

15 IR (KBr, cm⁻¹) 3420, 1740

NMR (CDCl₃) δ 8.3 (d, 1H), 8.14 (dd, 2H), 8.10 (d, 2H), 7.85 (d, 1H), 3.34 (s, 3H), 3.30 (s, 3H), 3.11 (s, 3H)

MS (-FAB) 1183 (M⁻)

20 The following are representative examples of rapamycin derivatives that can be conjugated to immunogenic carriers by the procedures described above or can be connected to another linker and then conjugated.

Example 18

25 Rapamycin 42-carbomethoxymethyl ether and Rapamycin 42-bis(carbomethoxymethyl ether)

Rapamycin (2.0 g, 2.187 mmol) and rhodium (II) acetate (0.37 g, 0.08 mmol) were heated to reflux in benzene and treated with a solution ethyl diazoacetate (500 ml) in benzene (10 ml) over 10 minutes. The solution was cooled to room temperature and was stirred overnight. TLC showed that the reaction was incomplete. Two additional portions of ethyldiazoacetate (3 ml) were added at 24 hour intervals. The mixture was concentrated and purified by flash chromatography over silica using ethyl acetate. This provided the 42-monoether (1 g) and the 31,42 diether (0.850 g) as oils. The 42-monoether was triturated in a mixture of hexane, ethyl acetate and dichloromethane over the weekend to give the product as a powder. The diether was purified on HPLC on a silica gel column with ethyl acetate as eluant. This provided the product as a solid.

- 26 -

Analytical data for the monoether:

Analysis Calc for C₅₅H₈₅NO₁₅: C, 66.04; H, 8.57; N, 1.40. Found: C, 65.29; H, 8.64; N, 1.60

IR (KBr, cm⁻¹) 3420, 1715

5 NMR (CDCl₃) δ 4.82 (s, 1H), 3.41 (s, 3H), 3.33 (s, 3H), 3.13 (s, 3H), 1.28 (t, 3H), 0.70 (q, 1H)

MS (-FAB) 999 (M⁻)

Analytical data for the diether:

10 Analysis Calc for C₅₉H₉₁NO₁₇: C, 65.23; H, 8.44; N, 1.29. Found: C, 63.29; H, 8.40; N, 1.44

IR (KBr, cm⁻¹) 1740

NMR (CDCl₃) δ 6.36 (q, 2H), 5.24 (s, 1H), 3.39 (s, 3H), 3.32 (s, 3H), 3.12 (s, 3H), 0.65 (q, 1H)

MS (-FAB) 1085 (M⁻)

15

Example 19

Rapamycin 42-(4-nitrophenyl)carbonate and Rapamycin 31,42-bis(4-nitrophenyl)carbonate

20 Rapamycin (0.450 g, 0.49 mmol) was dissolved in dry dichloromethane (10 ml) and cooled to 0°C. To this solution was added pyridine (0.4 ml, 5.7 mmol) and a crystal of 4-dimethyl aminopyridine. A solution of 4-nitrophenyl chloroformate (0.3 g 1.49 mmol) in dichloromethane (3 ml) was added. The solution was allowed to warm to room temperature overnight and was stirred at room temperature for 24 hours. The reaction was quenched into 0.1N HCl (5 ml) and the aqueous layer was washed with dichloromethane. The organic layer was dried over MgSO₄, filtered, and
25 evaporated in vacuo to afford a yellow solid. Chromatography over silica gel with 75% Ethyl acetate in hexane afforded 180 mg of the 42-monocarbonate and 47 mg of the 31,42-dicarbonate as yellow solids.

30

Example 20

42-O-(Phenoxythiocarbonyl)-rapamycin

35 Rapamycin (1.030 g, 1.12 mmol) was dissolved in dry dichloromethane (100 ml) and was cooled to 0°C. To this solution was added pyridine (0.27 ml, 3.33 mmol) and a crystal of 4-dimethyl aminopyridine. A solution of thiophenyl chloroformate (0.47 ml 1.49 mmol) in dichloromethane (5 ml) was added to the reaction mixture. The solution was allowed to warm to room temperature overnight and was stirred at room

- 27 -

temperature for 24 hours. The reaction was quenched into 0.1N HCl (5 ml) and the aqueous layer was washed with dichloromethane. The organic layer was dried over MgSO₄, filtered and evaporated *in vacuo* to afford a yellow solid. Chromatography on a 4 mm silica gel Chromatotron plate with a gradient of 40% to 70% ethyl acetate in hexane afforded 520 mg of the title compound as a yellow foam.

Analysis Calc for C₅₈H₈₃NOS₁₄: C, 66.32; H, 7.97; N, 1.33. Found: C, 66.48; H, 8.05; N, 1.12

IR (KBr, cm⁻¹) 3420, 1715

NMR (CDCl₃) δ 7.41 (t, 1H), 7.25 (t, 2H), 7.12 (d, 1H), 3.45 (s, 3H), 3.33 (s, 3H), 3.13 (s, 3H)

MS (-FAB) 1049 (M⁻)

Example 21

Rapamycin-O-carboxymethyl-27-oxime

To a solution of 600 mg (650 μM) of rapamycin in 6 mL of methanol was added at room temperature, 100 mg (1.2 mmol) of anhydrous sodium acetate and 140 mg (660 μM) of carboxymethoxylamine hemihydrochloride. After stirring overnight at room temperature, the reaction was complete. The reaction mixture was concentrated in vacuo and the residue was triturated with water. The solids were filtered and washed thoroughly with water. The product was dried under high vacuum to give 575 mg (89.7%) of a white solid. ¹³C and ¹H NMR indicated a mixture of E and Z isomers for the oxime derivative at position 27.

¹H NMR (CDCl₃, 400 MHz): 3.43 and 3.41 (2s, 3H, CH₃O), 3.30 (s, 3H, CH₃O), 3.18 and 3.12 (2s, 3H, CH₃O), 1.82 (s, 3H, CH₃C=C), 1.695 and 1.633 (2s, 3H, CH₃C=C); ¹³C NMR (CDCl₃, MHz): 215.8 (C=O), 211.5 (C=O), 194.5 (C=O), 191.0 (C=O), 172.5 (C=O), 169.0 (C=O), 168.5 (C=O), 167.0 (C=O), 161.5 (C=NOC), 160.0 (C=NOC), 140.0; MS (neg. ion FAB: 985 (M-H)⁻, 590, 167, 128, 97, 75 (100%)

Analysis Calcd for C₅₃H₈₂N₂O₁₅ · 0.15 H₂O : C 63.90; H 8.40; N 2.81

Found : C 63.81; H 8.41; N 2.85

The following compound was used in the generation of antibodies specific for rapamycin or a derivative thereof.

Example 22

Rapamycin 42-ester with glycylobiotin

To a solution of biotin (0.83 g, 3.4 mmol) in 60 mL of DMF was added glycine t-butyl ester hydrochloride (0.57 g, 3.4 mmol), N-methylmorpholine (0.92 mL, 8.36 mmol), 1-hydroxybenzotriazole (0.61 g, 3.99 mmol) and 1-(3-Dimethylaminopropyl)-3-ethylcarbo-diimide hydrochloride (0.65 g, 3.4 mmol). The reaction mixture was stirred at room temperature for 7 days. The DMF was concentrated, ethyl acetate was added, and the organic layer was washed with water, 0.5 N HCl, saturated sodium bicarbonate, and brine. The ethyl acetate layer was dried (MgSO₄) and concentrated to yield tert-butylglycylobiotin as a white solid which was primarily one spot on TLC (0.611 g, 1.71 mmol, 50%). Mass spec [M+H]⁺ at m/z 358.

To a solution of tert-butylglycylobiotin (0.271 g, 0.758 mmol) in CH₂Cl₂ (0.5 mL) was added 0.5 mL trifluoroacetic acid. The reaction mixture was stirred at room temperature for 2h, concentrated, and triturated with anhydrous diethyl ether. The off-white precipitate was collected to yield 0.209 g (0.694 mmol, 92%) of glycylobiotin. Mass spec [M+H]⁺ at m/z 302.


To a solution of glycylobiotin (0.65 g, 2.16 mmol) in 1-methylpyrrolidinone (5 mL) was added 6 mL of CH₂Cl₂, causing a precipitate to form which persisted even after the addition of 0.33 mL (2.36 mmol) of triethylamine. To this heterogenous solution was added 2 g (2.19 mmol) of rapamycin, 0.43 g (2.24 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, and 30 mg (2.46 mmol) of DMAP. After several hours, the reaction mixture became homogenous, and was stirred an additional four days. A large excess of ethyl acetate was added and the organic layer was washed with water, 0.5 N HCl, saturated sodium bicarbonate, and brine. The organic layer was dried (MgSO₄) and concentrated. The light yellow foam was triturated with hot anhydrous diethyl ether to yield 1.2 g of impure title compound as a light yellow solid. A portion (0.5 g) of this material was flash chromatographed in 5% MeOH/CHCl₃, and triturated again in hot ether to yield 87 mg of the title compound contaminated with a small amount of rapamycin. This material was rechromatographed (gradient 0-5% MeOH/CHCl₃), and triturated a final time with ether to yield 34 mg (0.028 mmol) of pure title compound as a white solid. Mass spec, negative FAB M⁻ at m/z 1196.

CLAIMS

What is claimed is:

1. A rapamycin conjugate of formula I, having the structure

5



wherein R¹ and R² are each, independently, hydrogen or -(R³-L-R⁴)_a;

L is a linking group;

- 10 R³ is selected from the group consisting of carbonyl, -S(O)-, -S(O)₂, -P(O)₂-, -P(O)(CH₃)-, -C(S)-, and -CH₂C(O)-;

R⁴ is a selected from the group consisting of carbonyl, -NH-, -S-, -CH₂-, and -O-;

a = 1 - 5;

x = 0 - 1;

- ```
15 y = 0 - 1;
```

z is from about 1 to about 120;

and Carrier is immunogenic carrier material, detector carrier material, or a solid matrix, or a salt thereof; with the proviso that R<sup>1</sup> and R<sup>2</sup> are not both hydrogen; and further provided that when a is greater than 1, each L group can be the same or different; and

- 20 still further provided that x is 0 if R<sup>1</sup> is hydrogen and y is 0 if R<sup>2</sup> is hydrogen, and if x and y are both 1, the Carrier moiety is the same in both cases.

2. An antibody, capable of specifically binding with rapamycin or a derivative thereof prepared against a conjugate of claim 1.



- 30 -

3. In an immunoassay method for determining levels of rapamycin or a derivative thereof, the improvement comprises employing an antibody prepared against a conjugate of claim 1.


5

4. In an immunoassay method for determining levels of rapamycin or a derivative thereof, the improvement comprises using a conjugate of claim 1 as a detector molecule.

5. A test kit for measuring levels of rapamycin or a derivative thereof comprising a rapamycin conjugate of claim 1 bound to a solid support and an antibody capable of specifically binding to rapamycin or a derivative thereof.

10

6. A rapamycin conjugate of formula II, having the structure



$R^1$  and  $R^2$  are each, independently, hydrogen, or  $-R^3-L-R^4-$ ;

$L$  is  $-A-(CR^5R^6)_b[B-(CR^7R^8)_d]_e-$

$A$  is  $-\text{CH}_2-$  or  $-\text{NR}^9-$ ;

20  $B$  is  $-\text{O}-$ ,  $-\text{NR}^9-$ ,  $-\text{S}-$ ,  $-\text{S}(\text{O})-$ , or  $-\text{S}(\text{O})_2-$ ;

$R^3$  is selected from the group consisting of carbonyl,  $-\text{S}(\text{O})-$ ,  $-\text{S}(\text{O})_2$ ,  $-\text{P}(\text{O})_2-$ ,  $-\text{P}(\text{O})(\text{CH}_3)-$ ,  $-\text{C}(\text{S})-$ , and  $-\text{CH}_2\text{C}(\text{O})-$ ;

$R^4$  is selected from the group consisting of carbonyl,  $-\text{NH}-$ ,  $-\text{S}-$ ,  $-\text{CH}_2-$ , and  $-\text{O}-$ ;


- 31 -

- R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup> are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, halo, hydroxy, trifluoromethyl, arylalkyl in which the alkyl portion contains 1-6 carbon atoms, aminoalkyl of 1-6 carbon atoms, hydroxyalkyl of 1-4 carbon atoms, alkoxy of 1-6 carbon atoms, carbalkoxy of 2-7 carbon atoms, cyano, amino, -CO<sub>2</sub>H, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or -CO<sub>2</sub>H;
- R<sup>9</sup> is hydrogen, alkyl of 1-6 carbon atoms, or aralkyl in which the alkyl portion contains 1-6 carbon atoms, providing that if more than one R<sup>9</sup> group is present they may be the same or different;
- b = 0-10;  
d = 0-10;  
e = 0-2;  
x = 0 - 1;  
y = 0 - 1;  
z is from about 1 to about 120;
- and Carrier is immunogenic carrier material, detector carrier material, or a solid matrix, or a salt thereof with the proviso that R<sup>1</sup> and R<sup>2</sup> are not both hydrogen; and further provided that when b is greater than 1, each of the CR<sup>5</sup>R<sup>6</sup> groups can be the same or different, and when d or e is greater than 1, each of the CR<sup>7</sup>R<sup>8</sup> groups can be the same or different; and still further provided that x is 0 if R<sup>1</sup> is hydrogen and y is 0 if R<sup>2</sup> is hydrogen, and if x and y are both 1, the Carrier moiety is the same in both cases.
7. The conjugate of claim 6, which is rapamycin 42-ester with succinic acid conjugate with keyhole limpet hemocyanin.
8. The conjugate of claim 6, which is rapamycin 42-ester with succinic acid conjugate with ovalbumin.
9. The conjugate of claim 6, which is rapamycin 42-ester with succinic acid conjugate with horseradish peroxidase.
10. The conjugate of claim 6, which is rapamycin 31,42-diester with glutaric acid conjugate with keyhole limpet hemocyanin.

- 32 -

11. The conjugate of claim 6, which is rapamycin 31,42-diester with glutaric acid conjugate with horseradish peroxidase.
12. An antibody, capable of specifically binding with rapamycin or a derivative thereof prepared against a conjugate of claim 6.
13. In an immunoassay method for determining levels of rapamycin or a derivative thereof, the improvement comprises employing an antibody prepared against a conjugate of claim 6.
14. In an immunoassay method for determining levels of rapamycin or a derivative thereof, the improvement comprises using a conjugate of claim 6 as a detector molecule.
15. A test kit for measuring levels of rapamycin or a derivative thereof comprising a rapamycin conjugate of claim 6 bound to a solid support and an antibody capable of specifically binding to rapamycin or a derivative thereof.
16. A rapamycin conjugate of formula III, having the structure

20




$R^1$  and  $R^2$  are each, independently, hydrogen or  $-(R^3-L^1-R^4)_f-(R^{10}-L^2-R^{11})_g$ -Carrier;  
 $L^1$  is  $-(CH_2)_h-CH(R^{12})-(CH_2)_j-$ ;

- 33 -

$L^2$  is  $-(CH_2)_k-D-(CH_2)_m-E-$ ;

D is  $-CH_2-$ ,  $-S-S-$ , or



;

E is  $-CH_2-$  or  $-\overset{\overset{O}{\parallel}}{C}-NH_2^+Cl^-$ ;

$R^3$  and  $R^{10}$  are each, independently, selected from the group consisting of carbonyl,  $-S(O)-$ ,  $-S(O)_2$ ,  $-P(O)_2-$ ,  $-P(O)(CH_3)-$ ,  $-C(S)-$ , and  $-CH_2C(O)-$ ;

$R^4$  and  $R^{11}$  are each, independently, selected from the group consisting of carbonyl,  $-NH-$ ,  $-S-$ ,  $-CH_2-$ , and  $-O-$ ;

$R^{12}$  is hydrogen, alkyl of 1-6 carbon atoms, arylalkyl in which the alkyl portion contains 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms,  $-(CH_2)_nCO_2R^{13}$ ,  $-(CH_2)_pNR^{14}R^{15}$ , carbamylalkyl of 2-3 carbon atoms, aminoalkyl of 1-4 carbon atoms, hydroxyalkyl of 1-4 carbon atoms, guanylalkyl of 2-4 carbon atoms, mercaptoalkyl of 1-4 carbon atoms, alkylthioalkyl of 2-6 carbon atoms, indolylmethyl, hydroxyphenylmethyl, imidazolylmethyl, halo, trifluoromethyl, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or  $-CO_2H$ ;

$R^{14}$ , and  $R^{15}$  are each, independently, hydrogen, alkyl of 1-6 carbon atoms, or arylalkyl in which the alkyl portion contains 1-6 carbon atoms;

$R^{13}$  is hydrogen, alkyl of 1-6 carbon atoms, arylalkyl in which the alkyl portion contains 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or  $-CO_2H$ ;

$f = 0-3$ ;

$g = 0-1$ ;

$h = 0-10$ ;

$j = 0-10$ ;

$k = 0-10$ ;

$m = 0-10$ ;

- 34 -

$n = 0-6$ ;

$p = 0-6$ ;

$x = 0-1$ ;

$y = 0-1$ ;

- 5     $z$  is from about 1 to about 120;  
and Carrier is immunogenic carrier material, detector carrier material, or a solid matrix,  
or a salt thereof with the proviso that  $R^1$  and  $R^2$  are not both hydrogen; and further  
provided that  $f$  and  $g$  are both not 0 and when  $f$  is greater than 1, each of the  $-(R^3-L^1-$   
 $R^4)-$  moieties can be the same or different; and still further provided that  $x$  is 0 if  $R^1$  is  
10    hydrogen and  $y$  is 0 if  $R^2$  is hydrogen; and if  $x$  and  $y$  are both 1, the Carrier moiety is  
the same in both cases.

17    The conjugate of claim 16, which is rapamycin 42-ester with 3-[3-(4-  
iminobutylthio)succinimidyl]phenacylglycine conjugate with horseradish peroxidase.

15

18.    The conjugate of claim 16, which is rapamycin 42 ester with (N-(3-  
carboxyphenyl)-3-thiosuccinimidyl)-glycine conjugate with horseradish peroxidase.

19.    An antibody, capable of specifically binding with rapamycin or a derivative  
20    thereof prepared against a conjugate of claim 16.

20.    In an immunoassay method for determining levels of rapamycin or a derivative  
thereof, the improvement comprises employing an antibody prepared against a conjugate  
of claim 16.


25

21.    In an immunoassay method for determining levels of rapamycin or a derivative  
thereof, the improvement comprises using a conjugate of claim 16 as a detector  
molecule.

30    22.    A test kit for measuring levels of rapamycin or a derivative thereof comprising a  
rapamycin conjugate of claim 16 bound to a solid support and an antibody capable of  
specifically binding to rapamycin or a derivative thereof.

- 35 -

23. A rapamycin conjugate of formula IV, having the structure



wherein  $R^{16}$  is  $-OCH_2(CH_2)_qR^4$  ;

5  $R^4$  is selected from the group consisting of carbonyl,  $-NH-$ ,  $-S-$ ,  $-CH_2-$ , and  $-O-$  ;

$q = 0 - 6$ ;

$z$  is from about 1 to about 120;

and Carrier is immunogenic carrier material, detector carrier material, or a solid matrix, or a salt thereof.

10 24. An antibody, capable of specifically binding with rapamycin or a derivative thereof prepared against a conjugate of claim 23.

25. In an immunoassay method for determining levels of rapamycin or a derivative thereof, the improvement comprises employing an antibody prepared against a conjugate of claim 23.

15 26. In an immunoassay method for determining levels of rapamycin or a derivative thereof, the improvement comprises using a conjugate of claim 23 as a detector molecule.


27. A test kit for measuring levels of rapamycin or a derivative thereof comprising a rapamycin conjugate of claim 23 bound to a solid support and an antibody capable of  
20 specifically binding to rapamycin or a derivative thereof.

- 36 -

28. A hybridoma cell line capable of producing antibodies specific for rapamycin or a derivative thereof which is designated as RAP-42-OVAF<sub>2</sub>#1hc.
29. A test kit for measuring levels of rapamycin or a derivative thereof, comprising a rapamycin specific antibody bound to a solid support.
- 5 30. A test kit for measuring levels of rapamycin or a derivative thereof, comprising a molecule bound to a solid support capable of capturing an antibody specific for rapamycin or a derivative thereof.
31. The test kit according to claim 31 wherein the bound molecule is goat anti-mouse antibody.
- 10 32. A process for preparing rapamycin conjugates including those of formula I and IV as defined above which comprises:  
reacting a compound of formula (V) or (VI):



or



- wherein  $R^{21}$  and  $R^{22}$  are each selected from hydrogen or  $-(R^3-L-R^4)_a-T^1$  providing that  $R^{21}$  and  $R^{22}$  are not both hydrogen (i.e. when both  $R^{21}$  and  $R^{22}$  are hydrogen the compound of formula (V) is rapamycin);  
 $R^{23}$  is  $-O(CH_2)(CH_2)_qR^4-T^1$ ;  
 20  $-(R^3-L-R^4)_a-$  is a group as defined above;  
 $T^1$  is an electrophilic or nucleophilic group depending on the value for  $R^4$ ; and  
 $q$  and  $R^4$  are as hereinbefore defined;  
 with a carrier material or matrix having available at least  $z$  nucleophilic or electrophilic groups; said carrier being represented by the formula



- (where Carrier and  $z$  are as defined above and  $T^2$  is a nucleophilic or electrophilic group of the carrier);  
 providing that in the formulae above when one of  $T^1$  and  $T^2$  is a nucleophilic group the other is an electrophilic group such that the bonding to the carrier is via a group  $R^4$  as  
 30 defined above.

# INTERNATIONAL SEARCH REPORT

Int. onal Application No

PCT/US 94/04463

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 A61K47/48 G01N33/74 G01N33/53 C12P21/08 G01N33/531  
C12N5/20 C07D498/18

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 A61K G01N C07K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages                                                        | Relevant to claim No. |
|------------|-------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| P,X        | WO,A,93 25533 (ABBOTT LABORATORIES) 23<br>December 1993<br>see page 7, line 19<br>see page 11, line 19 - page 12, line 2<br>see example 7 | 1-26                  |
| Y          | ---                                                                                                                                       | 1-32                  |
| Y          | US,A,5 164 495 (ABBOTT LABORATORIES) 17<br>November 1992                                                                                  | 1-32                  |
| A          | see column 3, line 65 - column 4, line 16;<br>claims                                                                                      | 1-26                  |
| P,A        | US,A,5 233 036 (P. F. HUGHES) 3 August<br>1993<br>see claim 1                                                                             | 1                     |
|            | ---                                                                                                                                       |                       |
|            | -/--                                                                                                                                      |                       |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

8 September 1994

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Berte, M



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 94/04463

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT |                                                                                                                                                                                                                                                                                                                     |                       |
|------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Category *                                           | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                                                                                  | Relevant to claim No. |
| A                                                    | US,A,5 177 203 (A. A. FAILLI) 5 January 1993<br>cited in the application<br>see claim 1<br>----                                                                                                                                                                                                                     | 1                     |
| P,A                                                  | WO,A,93 19752 (DANA-FARBER CANCER INSTITUTE) 14 October 1993<br>see claims 1,12,13<br>----                                                                                                                                                                                                                          | 1,4                   |
| A                                                    | WO,A,92 05179 (AMERICAN HOME PRODUCTS CORPORATION) 2 April 1992<br>see page 3, line 2; claims; examples<br>----                                                                                                                                                                                                     | 1-32                  |
| X                                                    | PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,<br>vol.88, July 1991, WASHINGTON US<br>pages 6229 - 6233<br>THOMAS HULTSCH ET AL. 'IMMUNOPHILIN LIGANDS DEMONSTRATE COMMON FEATURES OF SIGNAL TRANSDUCTION LEADING TO EXOCYTOSIS OR TRANSCRIPTION.'<br>See abstract<br>see page 6229<br>----                | 1,6,16                |
| P,X                                                  | JOURNAL OF THE AMERICAN CHEMICAL SOCIETY,<br>vol.116, March 1994, WASHINGTON, DC US<br>pages 2683 - 2684<br>YANQIU CHEN ET AL. 'CONFORMATIONAL CHANGES OF RAPAMYCIN AND ANALOGS UPON COMPLEXING WITH FKBP ASSOCIATED WITH ACTIVITY: AN APPLICATION OF SECOND DERIVATIVE CD SPECTROSCOPY.'<br>*see chart 1*<br>----- | 1,6,16                |

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
  
SEE ANNEX
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/202

CONTINUATION OF BOX I.2

IN VIEW OF THE LARGE NUMBER OF COMPOUNDS, WHICH ARE DESIGNED BY THE GENERAL FORMULAS OF CLAIMS 1, 6, 16, 23 AND ALSO IN VIEW OF THE DEFINITION OF PRODUCTS BY MEANS OF THEIR BIOLOGICAL, CHEMICAL AND OR PHARMACOLOGICAL PROPERTIES, THE SEARCH HAS TO BE RESTRICTED FOR ECONOMIC REASONS. THE SEARCH WAS LIMITED TO THE COMPOUNDS FOR WHICH PHARMACOLOGICAL DATA WAS GIVEN AND/OR THE COMPOUNDS MENTIONED IN THE CLAIMS OR EXAMPLES.  
(SEE GUIDELINES, PART B, CHAPTER III, PARAGRAPH 3.6)

PARTIALLY SEARCH CLAIMS: 1-6, 12-16, 19-27, 29-32

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 94/04463

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s)                                                                                                         | Publication<br>date                                                                          |
|-------------------------------------------|---------------------|------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| WO-A-9325533                              | 23-12-93            | AU-B- 4400593                                                                                                                      | 04-01-94                                                                                     |
| US-A-5164495                              | 17-11-92            | NONE                                                                                                                               |                                                                                              |
| US-A-5233036                              | 03-08-93            | NONE                                                                                                                               |                                                                                              |
| US-A-5177203                              | 05-01-93            | WO-A- 9318043<br>US-A- 5260299                                                                                                     | 16-09-93<br>09-11-93                                                                         |
| WO-A-9319752                              | 14-10-93            | AU-B- 3922493                                                                                                                      | 08-11-93                                                                                     |
| WO-A-9205179                              | 02-04-92            | AU-A- 8659991<br>CA-A- 2051781<br>EP-A- 0549727<br>HU-A- 65763<br>JP-T- 6501012<br>US-A- 5221670<br>CA-A- 2051782<br>US-A- 5130307 | 15-04-92<br>20-03-92<br>07-07-93<br>28-07-94<br>27-01-94<br>22-06-93<br>29-03-92<br>14-07-92 |